Evidence map›Paper›PMID 36864363›Full record

SynthesisEuropean child & adolescent psychiatry2024

Efficacy of cannabinoids in neurodevelopmental and neuropsychiatric disorders among children and adolescents: a systematic review.

Lauren J Rice, Lisa Cannon, Navin Dadlani, Melissa Mei Yin Cheung, Stewart L Einfeld, Daryl Efron, David R Dossetor, Elizabeth J Elliott

Open access · hybridAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in European child & adolescent psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
5.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Lauren J RiceThe University of Sydney, Faculty of Medicine and Health, Specialty of Child and Adolescent Health, Sydney, NSW, Australia. lauren.rice@sydney.edu.au.ORCID http://orcid.org/0000-0002-2315-7698
Lisa CannonThe University of Sydney, Faculty of Medicine and Health, Specialty of Child and Adolescent Health, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0003-1744-812X
Navin DadlaniThe University of Sydney, Faculty of Medicine and Health, Brain and Mind Centre, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0002-6202-1718
Melissa Mei Yin CheungThe University of Sydney, Faculty of Medicine and Health, Specialty of Child and Adolescent Health, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0001-7598-8648
Stewart L EinfeldThe University of Sydney, Faculty of Medicine and Health, Brain and Mind Centre, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0001-6940-5215
Daryl EfronDepartment of General Paediatrics, Health Services, Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Australia.ORCID http://orcid.org/0000-0003-2810-4496
David R DossetorSydney Children's Hospitals Network, Kids Research, Sydney, Australia.ORCID http://orcid.org/0000-0001-6282-445X
Elizabeth J ElliottThe University of Sydney, Faculty of Medicine and Health, Specialty of Child and Adolescent Health, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0002-6501-5487
The University of Sydney · AURoyal Children's Hospital · AUSydney Children’s Hospitals Network · AU

Funding

Ian Potter Foundation 31110414National Health and Medical Research Council 1110341Westpac Research Fellowhip 2021
6 · The paper itself

Abstract

A better understanding of the endocannabinoid system and a relaxation in regulatory control of cannabis globally has increased interest in the medicinal use of cannabinoid-based products (CBP). We provide a systematic review of the rationale and current clinical trial evidence for CBP in the treatment of neuropsychiatric and neurodevelopmental disorders in children and adolescents. A systematic search of MEDLINE, Embase, PsycINFO, and the Cochrane Central Register of Trials was performed to identify articles published after 1980 about CBP for medical purposes in individuals aged 18 years or younger with selected neuropsychiatric or neurodevelopmental conditions. Risk of bias and quality of evidence was assessed for each article. Of 4466 articles screened, 18 were eligible for inclusion, addressing eight conditions (anxiety disorders (n = 1); autism spectrum disorder (n = 5); foetal alcohol spectrum disorder (n = 1); fragile X syndrome (n = 2); intellectual disability (n = 1); mood disorders (n = 2); post-traumatic stress disorder (n = 3); and Tourette syndrome (n = 3)). Only one randomised controlled trial (RCT) was identified. The remaining seventeen articles included one open-label trial, three uncontrolled before-and-after trials, two case series and 11 case reports, thus the risk of bias was high. Despite growing community and scientific interest, our systematic review identified limited and generally poor-quality evidence for the efficacy of CBP in neuropsychiatric and neurodevelopmental disorders in children and adolescents. Large rigorous RCTs are required to inform clinical care. In the meantime, clinicians must balance patient expectations with the limited evidence available.

Indexed as

CannabinoidsNeurodevelopmental DisordersAdolescentChildHumansMental DisordersCannabinoidsCannabinoidsDevelopmental disabilityNeurodevelopmental disorderNeuropsychiatric disordersPaediatrics

Identifiers

PMID36864363
PMCPMC10869397
OpenAlexW4322761639

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.